Media & Investors
Transparency is important to us. Find important information about Kuros Biosciences here – from our corporate documents to our current share price.
20 Oct 2020
Kuros announces final result of capital increase – total gross proceeds of CHF 18.6 million raised
06 Oct 2020
Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting
Reports & corporate governance
Kuros Biosciences is fully committed to good corporate governance and adherence to high ethical standards. Our principles and rules on corporate governance and ethical conduct are articulated in the Articles of Association, the Internal Regulations, the charters of the committees of our board of directors, and our code of conduct.
Olav Zilian, MD, PhD, EMBA
Mirabaud Securities Ltd
David Sherman, Ph.D.(AC)
Please use the button below to view and download Analyst reports
|Mar 18, 2021||Kuros will publish its Annual Report for 2020|
|Apr 19, 2021||Kuros will hold its Annual Shareholders' Meeting|
|Aug 11, 2021||Kuros will publish its Half Year Report for H1 2021|